First experience of effectiveness and safety of bedaquiline for 18 months within an optimised regimen for XDR-TB. Issue 5 (25th February 2016)

• Record Type: Journal Article
• Authors: Lewis, Joseph M.; Hine, Paul; Walker, Jenny; Khoo, Saye H.; Taegtmeyer, Miriam; Squire, S. Bertel; Sloan, Derek J.
• Is Part Of: European respiratory journal. Volume 47:Issue 5(2016)
• Page Start: 1581
• Page End: 1584
• Publication Date: 2016-02-25
• Subjects: Respiratory organs -- Diseases -- Periodicals; Respiration -- Periodicals; 616.2
• DOI: 10.1183/13993003.01980-2015
• Languages: English
• ISSNs: 0903-1936

Abstract

Extensively drug-resistant (XDR) tuberculosis (TB) is a type of multidrug-resistant (MDR) TB that is resistant to isoniazid, rifampicin, fluoroquinolones and at least one injectable second-line drug. There are insufficient antibiotics for effective combination therapy and mortality exceeds 70% [1]. Following successful phase IIb trials [2] in 2013, the novel mycobacterial ATP-synthase inhibitor bedaquiline was approved in Europe and the USA for the first 24 weeks of MDR/XDR-TB treatment alongside a World Health Organization (WHO)-approved optimised background regimen. Phase III trials are ongoing but cohort data describe good early bacteriological outcomes in France [3, 4], Italy [5], the UK [6], the USA [7], India [8] and South Africa [9]. The first successful use of bedaquiline for 18 months for XDR-TB as part of an optimised background regimen http://ow.ly/XE34x